Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04532294




Registration number
NCT04532294
Ethics application status
Date submitted
27/08/2020
Date registered
31/08/2020
Date last updated
27/01/2022

Titles & IDs
Public title
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
Scientific title
A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects
Secondary ID [1] 0 0
BGB-DXP593-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Covid19 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BGB DXP593
Treatment: Drugs - Placebo

Experimental: BGB-DXP593: Dose Level A - Participants will receive BGB-DXP593 10 mg/kg on Day 1

Experimental: BGB-DXP593: Dose Level B - Participants will receive BGB-DXP593 30 mg/kg on Day 1

Experimental: Placebo - Placebo to match (PTM) BGB-DXP593 on Day 1


Treatment: Drugs: BGB DXP593
Administered intravenously (IV) as specified in the treatment arm

Treatment: Drugs: Placebo
Placebo to match BGB-DXP593
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Timepoint [1] 0 0
From the day of study drug administration until 30 days after dose (up to approximately 160 days)
Secondary outcome [1] 0 0
Number of Participants With Clinically Relevant Changes in Vital Signs and Electrocardiograms
Timepoint [1] 0 0
Up to approximately 160 days
Secondary outcome [2] 0 0
Number of Participants With Clinically Relevant Changes in Laboratory Parameters
Timepoint [2] 0 0
Up to approximately 160 days
Secondary outcome [3] 0 0
Maximum Observed Plasma Concentration (Cmax) of BGB-DXP593
Timepoint [3] 0 0
Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)
Secondary outcome [4] 0 0
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of BGB-DXP593
Timepoint [4] 0 0
Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)
Secondary outcome [5] 0 0
AUC From Time Zero to Time of Last Quantifiable Concentration (AUClast) of BGB-DXP593
Timepoint [5] 0 0
Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)
Secondary outcome [6] 0 0
AUC From Time Zero to Day 29 (AUC0-29) of BGB-DXP593
Timepoint [6] 0 0
Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, and 29
Secondary outcome [7] 0 0
Time to Maximum Observed Plasma Concentration (Tmax) of BGB-DXP593
Timepoint [7] 0 0
Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)
Secondary outcome [8] 0 0
Terminal Half Life (t1/2) of BGB-DXP593
Timepoint [8] 0 0
Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)
Secondary outcome [9] 0 0
Clearance (CL) of BGB-DXP593
Timepoint [9] 0 0
Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)
Secondary outcome [10] 0 0
Volume of Distribution (Vz) of BGB-DXP593
Timepoint [10] 0 0
Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)
Secondary outcome [11] 0 0
Immunogenic Response to BGB-DXP593 as Assessed by the Detection of Antidrug Antibodies (ADA)
Timepoint [11] 0 0
Up to approximately160 days

Eligibility
Key inclusion criteria
Key Inclusion Criteria :

1. Participants are in good general health as determined by the investigator or medically
qualified designee, based on a medical evaluation including medical history, physical
examination, laboratory tests and cardiac monitoring

2. Body weight = 50 kg and body mass index (BMI) within the range 18 to 32 kg/m2
(inclusive) Note: BMI = weight [kg] / (height [m])

3. Negative serum IgG to the SARS-CoV-2

4. Negative for COVID-19 based on the nasopharyngeal or oropharyngeal swab with the
method of real-time reverse transcription-polymerase chain reaction (rRT-PCR)

Key
Minimum age
18 Years
Maximum age
60 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
endocrinological, hematological, or neurological disorders capable of significantly
altering the absorption, metabolism, or elimination of drugs, constituting a risk to
the participant when taking the study drug; or interfering with the interpretation of
data

2. Any history of a severe allergic reaction prior to enrollment that has a reasonable
risk of recurrence during the study

3. Have a medical history of SARS infection

4. Any acute fever disease or infections

5. Any chronic or clinically significant medical condition that, in the opinion of the
investigator, would jeopardize the safety or rights of the participant, including but
not limited to: diabetes mellitus type I, chronic hepatitis; or clinically significant
forms of: drug or alcohol abuse, asthma (except for childhood asthma), autoimmune
disease, psychiatric disorders, or heart disease

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Basic Science
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/09/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
13/02/2021
Sample size
Target
Accrual to date
Final
18
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 0 0
Q Pharm Pty Limited - Herston
Recruitment postcode(s) [1] 0 0
4006 - Herston

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
BeiGene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary purpose of this study is to investigate the safety and tolerability of BGB-DXP593
administered intravenously as a single dose in healthy participants
Trial website
https://clinicaltrials.gov/ct2/show/NCT04532294
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
BeiGene
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04532294